Drugs / XP-DC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05773859 | Mar 2023 → Mar 2026 overdue | ovarian carcinoma | Radboud University Medical Center | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XP-DC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05773859 ↗ |
| Modality | Cell therapy | “a cDC1-based, autologous tumour lysate-loaded, DC product” PMID 41213670 ↗ Nov 2025 |